These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28501450)

  • 1. Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.
    Cota GF; de Sousa MR; de Assis TSM; Pinto BF; Rabello A
    Acta Trop; 2017 Aug; 172():186-191. PubMed ID: 28501450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients.
    Castro A; Carrillo E; San Martín JV; Botana L; Molina L; Matía B; Fernandez L; Horrillo L; Ibarra-Meneses A; Sanchez C; Ruiz-Giardin JM; Moreno J
    Acta Trop; 2016 Dec; 164():345-351. PubMed ID: 27693332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients.
    Silva-Freitas ML; Cota GF; Machado-de-Assis TS; Giacoia-Gripp C; Rabello A; Da-Cruz AM; Santos-Oliveira JR
    PLoS One; 2016; 11(12):e0167512. PubMed ID: 27907136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.
    Cota GF; de Sousa MR; de Mendonça AL; Patrocinio A; Assunção LS; de Faria SR; Rabello A
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2816. PubMed ID: 24743472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New world Leishmania spp. infection in people living with HIV: Concerns about relapses and secondary prophylaxis.
    Araújo CF; Oliveira IBN; Silva MVT; Pereira LIA; Pinto SA; Silveira MB; Dorta ML; Fonseca SG; Gomes RS; Ribeiro-Dias F
    Acta Trop; 2021 Dec; 224():106146. PubMed ID: 34562423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired Thymic Output Can Be Related to the Low Immune Reconstitution and T Cell Repertoire Disturbances in Relapsing Visceral Leishmaniasis Associated HIV/AIDS Patients.
    Silva-Freitas ML; Corrêa-Castro G; Cota GF; Giacoia-Gripp C; Rabello A; Teixeira Dutra J; de Vasconcelos ZFM; Savino W; Da-Cruz AM; Santos-Oliveira JR
    Front Immunol; 2020; 11():953. PubMed ID: 32508833
    [No Abstract]   [Full Text] [Related]  

  • 8.
    van Griensven J; Mengesha B; Mekonnen T; Fikre H; Takele Y; Adem E; Mohammed R; Ritmeijer K; Vogt F; Adriaensen W; Diro E
    Front Cell Infect Microbiol; 2018; 8():94. PubMed ID: 29651411
    [No Abstract]   [Full Text] [Related]  

  • 9. High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran.
    Rezaei Z; Sarkari B; Dehghani M; Layegh Gigloo A; Afrashteh M
    Parasitol Res; 2018 Aug; 117(8):2591-2595. PubMed ID: 29860572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
    Cota GF; de Sousa MR; Rabello A
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1153. PubMed ID: 21666786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Abongomera C; Diro E; Vogt F; Tsoumanis A; Mekonnen Z; Admassu H; Colebunders R; Mohammed R; Ritmeijer K; van Griensven J
    Clin Infect Dis; 2017 Oct; 65(10):1703-1710. PubMed ID: 29020196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of anti-Leishmania IgG3 and low CD4
    Kuschnir RC; Pereira LS; Dutra MRT; de Paula L; Silva-Freitas ML; Corrêa-Castro G; da Costa Cruz Silva S; Cota G; Santos-Oliveira JR; Da-Cruz AM
    BMC Infect Dis; 2021 Apr; 21(1):369. PubMed ID: 33874901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.
    Pintado V; Martín-Rabadán P; Rivera ML; Moreno S; Bouza E
    Medicine (Baltimore); 2001 Jan; 80(1):54-73. PubMed ID: 11204503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients.
    Molina I; Fisa R; Riera C; Falcó V; Elizalde A; Salvador F; Crespo M; Curran A; López-Chejade P; Tebar S; Pérez-Hoyos S; Ribera E; Pahissa A
    Am J Trop Med Hyg; 2013 Jul; 89(1):105-10. PubMed ID: 23629932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
    Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
    HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?
    van Griensven J; Diro E; Lopez-Velez R; Ritmeijer K; Boelaert M; Zijlstra EE; Hailu A; Lynen L
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3011. PubMed ID: 25101627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.